Hardman Johnston Global Advisors LLC Has $24.77 Million Holdings in IQVIA Holdings Inc. $IQV

Key Points

• Hardman Johnston reduced its stake in IQVIA by 8.2%, selling 9,869 shares to hold 109,907 shares valued at about $24.77 million (roughly 0.06% of IQVIA and its 25th largest holding).
• IQVIA beat quarterly estimates with EPS of $3.42 (vs. $3.40) and revenue of $4.36B (vs. $4.24B), up 10.3% year‑over‑year, and set FY2026 guidance of $12.55–$12.85 EPS.
• Analyst and institutional outlook: institutional investors own ~89.6% of the stock and analysts have a consensus "Buy" with an average price target of $226.63 versus the current share price near $167.50 (market cap ~$28.4B).

Hardman Johnston Global Advisors LLC lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 8.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 109,907 shares of the medical research company's stock after selling 9,869 shares during the quarter. IQVIA accounts for approximately 1.2% of Hardman Johnston Global Advisors LLC's holdings, making the stock its 25th largest holding. Hardman Johnston Global Advisors LLC owned 0.06% of IQVIA worth $24,774,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of IQV. Ameliora Wealth Management Ltd. acquired a new stake in shares of IQVIA in the 4th quarter valued at about $25,000. Physician Wealth Advisors Inc. raised its stake in shares of IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company's stock valued at $27,000 after purchasing an additional 134 shares during the period. Westside Investment Management Inc. raised its stake in shares of IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company's stock valued at $30,000 after purchasing an additional 101 shares during the period. Measured Wealth Private Client Group LLC acquired a new stake in shares of IQVIA in the third quarter valued at about $30,000. Finally, Atlantic Union Bankshares Corp acquired a new stake in shares of IQVIA in the third quarter valued at about $36,000. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Trading Up 0.1%

Shares of NYSE:IQV opened at $167.49 on Monday. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04. The stock has a market cap of $28.42 billion, a PE ratio of 21.31, a P/E/G ratio of 1.62 and a beta of 1.39. The business has a 50 day moving average of $173.38 and a 200-day moving average of $204.31. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The company had revenue of $4.36 billion during the quarter, compared to analysts' expectations of $4.24 billion. During the same quarter in the previous year, the company posted $3.12 earnings per share. The business's revenue was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on IQV. Mizuho set a $215.00 target price on IQVIA in a research report on Monday, February 23rd. Barclays upgraded IQVIA from an "equal weight" rating to an "overweight" rating and set a $210.00 price target for the company in a report on Friday, March 6th. UBS Group reduced their price target on IQVIA from $280.00 to $240.00 and set a "buy" rating for the company in a report on Friday, February 6th. Weiss Ratings reiterated a "hold (c)" rating on shares of IQVIA in a report on Thursday, January 22nd. Finally, Royal Bank Of Canada initiated coverage on IQVIA in a report on Tuesday, March 3rd. They set an "outperform" rating and a $221.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, IQVIA currently has an average rating of "Buy" and a consensus price target of $226.63.

IQVIA Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.